Victor Mangas Sanjuan

List of Publications by Year
in descending order

56	797	516215 16	552369 26
papers	citations	h-index	g-index

60	60	60	1268
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Quantitative assessment of the exposureâ€“efficacy relationship of glucocerebrosidase using Markovian elements in Gaucher patients treated with enzyme replacement therapy. British Journal of Clinical Pharmacology, 2022, 88, 2727-2737.	1.1	0
2	Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis. Pharmaceutics, 2022, 14, 654.	2.0	9
3	Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series. Pharmaceutics, 2022, 14, 1010.	2.0	7
4	Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics. European Journal of Pharmaceutical Sciences, 2022, 174, 106198.	1.9	1
5	Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. British Journal of Clinical Pharmacology, 2021, 87, 905-915.	1.1	6
6	Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making. Pharmaceutics, 2021, 13, 709.	2.0	9
7	Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics. Pharmaceutics, 2021, 13, 935.	2.0	14
8	The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives. Pharmaceutics, 2021, 13, 1016.	2.0	9
9	Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. Cancers, 2021, 13, 5049.	1.7	2
10	Estimators and confidence intervals of <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.svg"><mml:msub><mml:mi>f</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math> using bootstrap methodology for the comparison of dissolution profiles. Computer Methods and Programs in Biomedicine, 2021, 212, 106449.	2.6	3
11	Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 300-308.	0.7	7
12	EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma. Oncologist, 2020, 25, 1067-1074.	1.9	2
13	Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. Pharmaceutics, 2020, 12, 1226.	2.0	4
14	Influence of Inter- and Intra-Batch Variability on the Sample Size Required for Demonstration of Equivalent Microstructure of Semisolid Dosage Forms. Pharmaceutics, 2020, 12, 1159.	2.0	8
15	Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease. Pharmaceutics, 2020, 12, 1147.	2.0	0
16	Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice. Pharmaceutics, 2020, 12, 975.	2.0	7
17	Comparison of free software platforms for the calculation of the 90% confidence interval of f2 similarity factor by bootstrap analysis. European Journal of Pharmaceutical Sciences, 2020, 146, 105259.	1.9	11
18	A multilevel object-oriented modelling methodology for physiologically-based pharmacokinetics (PBPK): Evaluation with a semi-mechanistic pharmacokinetic model. Computer Methods and Programs in Biomedicine, 2020, 189, 105322.	2.6	6

#	ARTICLE	IF	CITATIONS
19	STUDY OF EXPECTATIONS, LEARNING ABILITY AND SATISFACTION THROUGH THE ERASMUS + PROGRAM. EDULEARN Proceedings, 2020, , .	0.0	0
20	DEVELOPMENT OF AN OPEN SOURCE PLATFORMS FOR IMPROVING THE LEARNING PROCESS IN PHARMACY. , 2020, , .		0
21	Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration. Pharmaceutics, 2019, 11, 365.	2.0	86
22	Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the Demonstration of Equivalence. Pharmaceutics, 2019, 11, 503.	2.0	17
23	Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation. European Journal of Pharmaceutical Sciences, 2018, 119, 200-207.	1.9	2
24	Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter. European Journal of Pharmaceutical Sciences, 2018, 117, 193-203.	1.9	5
25	Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 96-104.	1.3	9
26	Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and iorÂ®EPOCIM in New Zealand rabbits. European Journal of Pharmaceutical Sciences, 2018, 120, 123-132.	1.9	0
27	Target-Site Investigation for the Plasma Prolactin Response: Mechanism-Based Pharmacokinetic-Pharmacodynamic Analysis of Risperidone and Paliperidone in the Rat. Drug Metabolism and Disposition, 2017, 45, 152-159.	1.7	4
28	Commentary on the MID3 Good Practices Paper. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 416-417.	1.3	18
29	Enhancing Oral Absorption of Î²-Lapachone: Progress Till Date. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 1-10.	0.6	6
30	IVIVC approach based on carbamazepine bioequivalence studies combination. Die Pharmazie, 2017, 72, 449-455.	0.3	12
31	ARE SHORT AND TEST QUESTIONS ADEQUATELY BALANCED?. , 2017, , .		0
32	BEST PREDICTOR OF FINAL MARK. , 2017, , .		0
33	Importance and applications of cell- and tissue-based in vitro models for drug permeability screening in early stages of drug development. , 2016, , 3-29.		10
34	Assessment of the Regulatory Methods for the Comparison of Highly Variable Dissolution Profiles. AAPS Journal, 2016, 18, 1550-1561.	2.2	18
35	Population pharmacokinetic model of lithium and drug compliance assessment. European Neuropsychopharmacology, 2016, 26, 1868-1876.	0.3	8
36	Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its Oâ€demethyl metabolite on pupil diameter and nociception in healthy subjects. British Journal of Clinical Pharmacology, 2016, 82, 92-107.	1.1	6

#	Article	IF	Citations
37	Intestinal Permeability of Î²-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 795-806.	0.6	7
38	Semimechanistic Cell-Cycle Typeâ€“Based Pharmacokinetic/Pharmacodynamic Model of Chemotherapy-Induced Neutropenic Effects of Diflomotecan under Different Dosing Schedules. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 55-64.	1.3	26
39	Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexketoprofen Tablets. Molecular Pharmaceutics, 2015, 12, 3194-3201.	2.3	11
40	In vitroâ€“in vivocorrelations: general concepts, methodologies and regulatory applications. Drug Development and Industrial Pharmacy, 2015, 41, 1935-1947.	0.9	36
41	Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties. Journal of Medicinal Chemistry, 2015, 58, 5825-5841.	2.9	88
42	Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients. European Journal of Pharmaceutical Sciences, 2015, 73, 57-63.	1.9	2
43	Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid. European Journal of Pharmaceutical Sciences, 2015, 74, 86-94.	1.9	6
44	Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug. Molecular Pharmaceutics, 2015, 12, 3167-3174.	2.3	26
45	Drug gastrointestinal absorption in rat: Strain and gender differences. European Journal of Pharmaceutical Sciences, 2015, 78, 198-203.	1.9	15
46	Tubulin acetylation promoting potency and absorption efficacy of deacetylase inhibitors. British Journal of Pharmacology, 2015, 172, 829-840.	2.7	17
47	Variability of permeability estimation from different protocols of subculture and transport experiments in cell monolayers. Journal of Pharmacological and Toxicological Methods, 2015, 71, 21-32.	0.3	31
48	A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. European Journal of Medicinal Chemistry, 2014, 83, 366-373.	2.6	22
49	Modified Nonsink Equation for Permeability Estimation in Cell Monolayers: Comparison with Standard Methods. Molecular Pharmaceutics, 2014, 11, 1403-1414.	2.3	18
50	Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract. Xenobiotica, 2013, 43, 745-754.	0.5	5
51	Innovative in Vitro Method To Predict Rate and Extent of Drug Delivery to the Brain across the Bloodâ€“Brain Barrier. Molecular Pharmaceutics, 2013, 10, 3822-3831.	2.3	19
52	Ion-pair strategy for enabling amifostine oral absorption: Rat in situ and in vivo experiments. European Journal of Pharmaceutical Sciences, 2013, 49, 499-504.	1.9	28
53	Semisynthesis, Cytotoxic Activity, and Oral Availability of New Lipophilic 9-Substituted Camptothecin Derivatives. ACS Medicinal Chemistry Letters, 2013, 4, 651-655.	1.3	17
54	In vitroâ€“in situ permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfate. European Journal of Drug Metabolism and Pharmacokinetics, 2012, 37, 65-75.	0.6	15

#	Article	IF	Citations
55	In Silico Prediction of Caco‚Ä2 Cell Permeability by a Classification QSAR Approach. Molecular Informatics, 2011, 30, 376-385.	1.4	76
56	Drug penetration across the blood‚Ä“brain barrier: an overview. Therapeutic Delivery, 2010, 1, 535-562.	1.2	24